Author: Polanco, Laura C. ; Zeitlin, Larry ; Ulrich, Rainer G. ; Herbert, Andrew S. ; Slough, Megan M. ; Wec, Anna Z. ; O’Brien, Cecilia M. ; Dye, John M. ; Walker, Laura M. ; Abelson, Dafna M. ; Bornholdt, Zachary A. ; Bakken, Russell R. ; Forsell, Mattias N. E. ; Jangra, Rohit K. ; Guardado-Calvo, Pablo ; Serris, Alexandra ; Mittler, Eva ; Geoghegan, James C. ; Bradfute, Steven B. ; Strandin, Tomas ; Tynell, Janne ; Vapalahti, Olli ; Chandran, Kartik ; Wigren-Byström, Julia ; Pehau-Arnaudet, Gerard ; Ahlm, Clas ; Rey, Felix A. ; Keller, Markus ; Sakharkar, Mrunal

The rodent-borne hantavirus Puumala virus (PUUV) and related agents cause hemorrhagic fever with renal syndrome (HFRS) in humans. Other hantaviruses, including Andes virus (ANDV) and Sin Nombre virus, cause a distinct zoonotic disease, hantavirus cardiopulmonary syndrome (HCPS). Although these infections are severe and have substantial case fatality rates, no FDA-approved hantavirus countermeasures are available. Recent work suggests that monoclonal antibodies may have therapeutic utility. We describe here the isolation of human neutralizing antibodies (nAbs) against tetrameric Gn/Gc glycoprotein spikes from PUUV-experienced donors. We define a dominant class of nAbs recognizing the “capping loop” of Gn that masks the hydrophobic fusion loops in Gc. A subset of nAbs in this class, including ADI-42898, bound Gn/Gc complexes but not Gn alone, strongly suggesting that they recognize a quaternary epitope encompassing both Gn and Gc. ADI-42898 blocked the cell entry of seven HCPS- and HFRS-associated hantaviruses, and single doses of this nAb could protect Syrian hamsters and bank voles challenged with the highly virulent HCPS-causing ANDV and HFRS-causing PUUV, respectively. ADI-42898 is a promising candidate for clinical development as a countermeasure for both HCPS and HFRS, and its mode of Gn/Gc recognition informs the development of broadly protective hantavirus vaccines.

100 Deals associated with ADI-42898

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hantavirus Infections	Preclinical	FR	Institut Pasteur	16 Mar 2022
Hantavirus Infections	Preclinical	US	Invivyd, Inc.	16 Mar 2022
Hantavirus Infections	Preclinical	US	Adimab LLC	16 Mar 2022
Hantavirus Infections	Preclinical	US	Mapp Biopharmaceutical, Inc.	16 Mar 2022
Hantavirus Infections	Preclinical	US	Albert Einstein College of Medicine, Inc.	16 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ADI-42898

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation